Fidelity Investments’s NeuroSense Therapeutics NRSN Stock Holding History

Fidelity Investments’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4	Buy	+1	New	+$10	﹤0.01%	5746

Other funds holding NRSN

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Fidelity Investments's NRSN Position: Q3 2026 in Review

Fidelity Investments opened a new position in NeuroSense Therapeutics (NRSN) in Q3 2026: 1 share worth $4. The stake represents ﹤0.01% of the portfolio and ranks #5746 among its holdings.

4 funds tracked by Wall St. Rank hold NRSN as of Q3 2026.

Fidelity Investments held 1 share of NeuroSense Therapeutics worth $4 as of Q3 2026.
NeuroSense Therapeutics was a new Fidelity Investments position in Q3 2026.
NeuroSense Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #5746 holding.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.